Granulomatosis With Polyangiitis Clinical Trial
— SATELITEOfficial title:
Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis
The purpose of this study is to identify the most promising therapeutic strategy for patients with granulomatosis with polyangiitis and inadequate response to standard of care therapy. It will evaluate the efficacy to induce remission of three different salvage strategies including: a combination of rituximab with addition of a conventional disease-modifying antirheumatic drugs (either methotrexate, azathioprine or mycophenolate mofetil, but preferentially methotrexate); tocilizumab; or abatacept.
Status | Not yet recruiting |
Enrollment | 42 |
Est. completion date | January 2027 |
Est. primary completion date | September 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Newly diagnosed or relapsing granulomatosis with polyangiitis according to American College of Rheumatology criteria, EMA classification algorithm and/or the 2012 revised Chapel Hill Consensus Conference definition. - Aged 18 years or older - Active clinical manifestations attributable to GPA - An inadequate response to previous standard of care therapy including 1. Both a combination of glucocorticoids plus cyclophosphamide and a combination of glucocorticoids plus rituximab 2. Or an inadequate response to a combination of glucocorticoids plus rituximab and a contraindication to cyclophosphamide - An inadequate response to treatment defined as follows: 1. A progressive disease unresponsive to previous standard of care therapy after 12 weeks of treatment 2. Or a lack of response, defined as < 50% reduction in the disease activity score, after 12 weeks of treatment 3. Or a persistent active disease attributable to either a vasculitic or a granulomatous manifestation of GPA that requires the maintenance of corticosteroids = 7.5 mg/day of equivalent prednisone after = 12 weeks of treatment. - A stable dose of oral glucocorticoids of = 7.5 mg/day of equivalent prednisone within the 4 weeks before enrollment. Pulses of methylprednisolone (1 to 3 pulses of 7.5 to 15 mg/kg each; = 1000 mg) are allowed if necessary, according to severity before starting the experimental treatment. - A stable dose of conventional disease-modifying anti-rheumatic drugs (cDMARD) within 4 weeks before enrollment if the patient is currently treated with a cDMARD - Patients must have the ability to understand the requirements of the study, provide written informed consent prior to participation in the study (including consent for the use and disclosure of research-related health information) and comply with the study protocol procedures (including required study visits) - Patients must have an affiliation with a mode of social security (profit or being entitled) Exclusion Criteria: - An allergy or hypersensitivity to monoclonal antibodies or either of the study drugs (rituximab, abatacept or tocilizumab) or to their excipients - A previous treatment with a combination of rituximab plus a cDMARD, with abatacept, or with tocilizumab - A contraindication to a combination of rituximab plus a cDMARD, to abatacept, or to tocilizumab (including an ongoing infection; history of recent cancer <5 years before enrollment, except for cured non-melanoma skin cancer); pregnancy; and breastfeeding. - Patients with severe vasculitis manifestations that requires plasma exchange therapy including severe renal failure with a creatinine level =350 µmol/L or severe alveolar haemorrhage - Patients with vasculitis in remission - Patients with symptoms attributable to chronic and non-active GPA - Patients with severe cardiac failure defined as class IV in New York Heart Association - Patients with acute infections or chronic active infections (including HIV, HBV or HCV) - Patients with active cancer or recent cancer (<5 years), except basocellular carcinoma and prostatic cancer of low activity controlled by hormonal treatment - Pregnant women and lactation. All women with childbearing potential are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception from the date of consent through the end of the study, and for women who are taking abatacept through 14 weeks after the last treatment administration, for women who are taking tocilizumab through 3 months after the last treatment administration, for women who are taking rituximab in combination with methotrexate through 6 months after the last treatment administration, for women who are taking rituximab in combination with mycofenolate mofetil or with azathioprine through 3 months after the last treatment administration - Patients with other uncontrolled diseases, including drug or alcohol abuse, severe psychiatric diseases, that could interfere with participation in the trial according to the protocol - Patients included in other investigational therapeutic study within the previous 3 months - Patients suspected not to be observant to the proposed treatments - Laboratory parameter exclusions 1. aspartate or alanine aminotransferase (AST/SGOT or ALT/SGPT) > 5 times upper limit of normal 2. Platelet count <100.000/mm3 3. White blood cell count <2000/mm3 |
Country | Name | City | State |
---|---|---|---|
France | Hôpital de la Croix Saint Simon | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | URC-CIC Paris Descartes Necker Cochin |
France,
Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, Sabbadini MG, Doglioni C, Dagna L. Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. Semin Arthritis Rheum. 2015 Aug;45(1):48-54. doi: 10.1016/j.semarthrit.2015.02.002. Epub 2015 Feb 20. — View Citation
Berti A, Warner R, Johnson K, Cornec D, Schroeder DR, Kabat BF, Langford CA, Kallenberg CGM, Seo P, Spiera RF, St Clair EW, Fervenza FC, Stone JH, Monach PA, Specks U, Merkel PA; RAVE-ITN Research Group. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. J Autoimmun. 2019 Dec;105:102302. doi: 10.1016/j.jaut.2019.07.001. Epub 2019 Jul 15. — View Citation
Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007 May;66(5):605-17. doi: 10.1136/ard.2006.062711. Epub 2006 Dec 14. — View Citation
Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, Reinhold-Keller E, Gross WL. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012 Mar;71(3):327-33. doi: 10.1136/ard.2011.153601. Epub 2011 Oct 21. — View Citation
Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, Ytterberg SR, Hoffman GS, Krischer JP, Merkel PA; Vasculitis Clinical Research Consortium. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis. 2014 Jul;73(7):1376-9. doi: 10.1136/annrheumdis-2013-204164. Epub 2013 Dec 9. — View Citation
Sakai R, Kondo T, Kurasawa T, Nishi E, Okuyama A, Chino K, Shibata A, Okada Y, Takei H, Nagasawa H, Amano K. Current clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review. Clin Rheumatol. 2017 Oct;36(10):2383-2392. doi: 10.1007/s10067-017-3752-0. Epub 2017 Jul 21. — View Citation
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905. — View Citation
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalcindag N, Jayne DR, Mukhtyar C. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23. Erratum In: Ann Rheum Dis. 2017 Aug;76(8):1480. Ann Rheum Dis. 2022 Jun;81(6):e109. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with a response or a remission | defined according to the EULAR recommendations. Remission is defined as the absence of disease activity attributable to active disease qualified by the need for ongoing stable maintenance immunosuppressive therapy. The term ''active disease'' is not restricted to vasculitis only, but also includes other inflammatory features like granulomatous inflammation. Response is defined as a 50% reduction of disease activity score and absence of new manifestations. | week 12 | |
Secondary | Proportion of patients with a response or a remission at week 26 and 52. | according to the EULAR recommendations | week 26 and 52 | |
Secondary | Physician's and patient's global assessment of disease activity | The difference between the physician's and patient's global assessment of disease activity between baseline and week 12 and between baseline and week 52 using a scale ranging from 0 to 100, with higher scores indicating more activity. | week 12 and 52 | |
Secondary | Patient-reported outcomes | The patient-reported outcomes (PRO) including the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire, a 29-item profile measure comprising six domains, with higher scores meaning more active disease, at week 12, 24, and 52 after randomization, and during the long-term follow-up. | week 12, 24 and 52 | |
Secondary | Adverse events | The number of adverse events, expressed as adverse events according to the CTCAE toxicity grading system per patient-year at week 26 and 52 for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorrhagic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions | week 26 and 52 | |
Secondary | Corticosteroids use | The area under the curve for corticosteroids at week 26 and 52 | week 26 and 52 | |
Secondary | Vasculitis Damage Index | The Vasculitis Damage Index (VDI, scoring from 0 to 58, higher scores indicating more damage) at week 26 and 52 | week 26 and 52 | |
Secondary | Health Assessment Questionnaire (HAQ) | ranging from 0 to 3, with higher scores indicating worse functional impairment | week 26 and 52 | |
Secondary | Short Form 36 (SF-36) Health questionnaire | scores range from 0 to 100 for each component, with lower scores indicating greater impairment of quality of life | week 26 and 52 | |
Secondary | ANCA titers | Evolution of ANCA titers in the treatment groups | week 26 and 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01731561 -
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
|
Phase 3 | |
Completed |
NCT01862068 -
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
|
||
Completed |
NCT01750697 -
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
Phase 2 | |
Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
Terminated |
NCT01586858 -
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
|
N/A | |
Active, not recruiting |
NCT03919435 -
TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
|
Phase 1/Phase 2 | |
Terminated |
NCT05376319 -
PR3-AAV Resilient Remission or PRRR
|
Phase 2 | |
Not yet recruiting |
NCT05353179 -
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
|
Early Phase 1 | |
Completed |
NCT02169219 -
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
|
Phase 4 | |
Completed |
NCT01613599 -
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
||
Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
Recruiting |
NCT04944524 -
Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA
|
Phase 4 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Completed |
NCT03410290 -
Journey of Patients With Vasculitis From First Symptom to Diagnosis
|
||
Recruiting |
NCT03482479 -
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
|
Phase 2 | |
Active, not recruiting |
NCT01940094 -
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
|
Phase 3 | |
Recruiting |
NCT01405807 -
Alemtuzumab for ANCA Associated Refractory Vasculitis
|
Phase 4 | |
Active, not recruiting |
NCT01933724 -
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
|
Phase 3 | |
Completed |
NCT05703802 -
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
|
||
Active, not recruiting |
NCT03967925 -
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
|
Phase 2 |